Alpha emitter radium-223 and survival in metastatic prostate cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F13%3AE0103552" target="_blank" >RIV/00843989:_____/13:E0103552 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/13:00059318

Výsledek na webu

<a href="http://dx.doi.org/10.1056/NEJMoa1213755" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1213755</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1213755" target="_blank" >10.1056/NEJMoa1213755</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Alpha emitter radium-223 and survival in metastatic prostate cancer

Popis výsledku v původním jazyce

Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men withcastration-resistant prostate cancer and bone metastases. Methods: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed th

Název v anglickém jazyce

Alpha emitter radium-223 and survival in metastatic prostate cancer

Popis výsledku anglicky

Background: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men withcastration-resistant prostate cancer and bone metastases. Methods: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed th

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

369

Číslo periodika v rámci svazku

n. 3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

"p. 213-223"

Kód UT WoS článku

000321945800007

EID výsledku v databázi Scopus

—